The state of Nevada currently has 7 active clinical trials seeking participants for Atopic Dermatitis research studies. These trials are conducted in various cities, including Las Vegas, Henderson, Reno and Pahrump.
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)
NCT05704738
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subjects.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
06/19/2024
Locations: Skin Cancer and Dermatology Institute, Reno, Nevada
Conditions: Atopic Dermatitis
Register for Updates
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
06/19/2024
Locations: Jubilee Clinical Research Inc, Las Vegas, Nevada +3 locations
Conditions: Atopic Dermatitis
Register for Updates
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741
Recruiting
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis. The estimated duration is 15-35 days for screening and then up to approximately day 378 (last dose on day 280 + 98 days safety follow-up) for all patients. Patients with a response at Week 16 (end of induction therapy) will be re-randomized for... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/06/2024
Locations: Jubilee Clinical Research, Las Vegas, Nevada +1 locations
Conditions: Moderate to Severe Atopic Dermatitis
Register for Updates
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD
NCT06224192
Recruiting
The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
06/05/2024
Locations: Excel Clinical Research, Las Vegas, Nevada +2 locations
Conditions: Atopic Dermatitis
Register for Updates
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).
NCT05935085
Recruiting
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/04/2024
Locations: AnaptysBio Investigative Site 10-118, Las Vegas, Nevada +1 locations
Conditions: Atopic Dermatitis Eczema
Register for Updates
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
NCT05694884
Recruiting
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: ASLAN Investigative Site, Las Vegas, Nevada
Conditions: Atopic Dermatitis
Register for Updates
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT05048056
Recruiting
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/04/2022
Locations: AkesoBio Investigative Site 2015, Las Vegas, Nevada
Conditions: Atopic Dermatitis
Register for Updates